87 results about "Proinflammatory cytokine" patented technology

The invention relates to the field of medicinal chemistry, and particularly discloses a piperidine derivative as well as a pharmaceutical composition, application and a preparation method thereof. The piperidine derivative has the following general formula. The piperidine derivative can be effectively used for treating or preventing multiple sclerosis, and shows an unexpected synergistic effect in an animal model: the piperidine derivative not only can significantly improve neurological function impairment and promote recovery, but also can deeply reduce the levels of key proinflammatory cytokines IFN-gamma and IL-17 at the same time. The invention provides a novel small molecule candidate drug with central permeability, neuroprotection and comprehensive immune regulation functions for treatment of multiple sclerosis.

The invention provides a compound probiotic for relieving anxiety behaviors and application of the compound probiotic. The compound probiotic comprises bifidobacterium animalis YRK-12 (the preservation number is CGMCC (China General Microbiological Culture Collection Center) NO.28597) and lactobacillus rhamnosus LRa-Y8 (the preservation number is CGMCC NO.34186). The invention finds that the two bacteria are compounded and can be matched and promoted with each other, and have a synergistic effect on the aspect of preventing and treating anxiety disorder, which is specifically shown as follows: the reduction of center lattice movement time and percentage caused by LPS (Lipopolysaccharide) is relieved; the increase of mouse serum proinflammatory cytokines caused by LPS is improved; the increase of mouse brain tissue proinflammatory cytokines caused by LPS is improved. Under the condition that the using amount of the bacteria is consistent, the effect of the compounding of the two bacteria on improving the anxiety-like behavior induced by the LPS is obviously improved. Meanwhile, the two bacteria are probiotics, so that the product is safe and is not easy to generate resistance.

The invention belongs to the technical field of engineered probiotics, and particularly relates to engineered probiotics for radiosensitization and tumor metabolism regulation as well as a preparation method and application of the engineered probiotics. The engineering probiotics comprise probiotics and core-shell type metal nanoparticles which are loaded on the probiotics and are synthesized through a biological directional mineralization effect; the core of the core-shell type metal nanoparticle is a palladium element, and the outer layer of the core-shell type metal nanoparticle is a palladium element and a gold element. The engineering probiotics provided by the invention have excellent enzyme catalysis performance and can target and retain in tumor sites, and through the synergistic effect of all components in the engineering probiotics, adenosine metabolism is effectively inhibited, secretion of pro-inflammatory cytokines is enhanced, tumor microenvironment is promoted to be converted into an inflammatory state, up-regulation of immune checkpoints is inhibited, and the immune checkpoints are inhibited. And T cells are inhibited from being transformed into depletion phenotype and transformed into effect type from depletion type. After the SBRT and the immune checkpoint inhibitor are combined for use, the growth of tumors can be effectively inhibited, and the effect of enhancing immune radiotherapy is achieved.

The invention relates to the technical field of microorganisms, in particular to bifidobacterium animalis with a depression improving effect and application of the bifidobacterium animalis. Experimental results show that the bifidobacterium animalis CP-9 for preventing and relieving depression, provided by the invention, can reduce the content of proinflammatory cytokines in serum of depression mice. Therefore, the bifidobacterium animalis CP-9 has a good development prospect in the aspect of preparing products for preventing and / or treating depression or in the aspect of preparing products for reducing the content of pro-inflammatory cytokines in serum of depressive mice.

The invention discloses an adipose-derived stem cell exosome compound loaded with silver nanoparticles and application of the adipose-derived stem cell exosome compound loaded with the silver nanoparticles, and ADSC-Exos loaded with the silver nanoparticles is developed by integrating AgNPs into an exosome of ADSCs. In vivo, the Exo-AgNPs can accelerate healing of infected wounds by reducing bacterial colonization and promoting collagen deposition, angiogenesis and M2 type macrophage polarization. In vitro, the Exo-AgNPs activates the functions of fibroblasts and vascular endothelial cells, and shows an excellent antibacterial property. In addition, the Exo-AgNPs induces polarization of M2 type macrophages and inhibits secretion of proinflammatory cytokines by activating autophagy. The results show that Exo-AgNPs is expected to become an ideal biological material for treating infected wounds.

The invention belongs to the field of biological medicine, and particularly relates to a CD3-LILRB4 bispecific antibody and application thereof. The invention provides a novel bispecific antibody with high activity and low toxicity, the bispecific antibody can be combined with CD3 and LILRB4 so as to promote T cell activation and effectively promote PBMC (peripheral blood mononuclear cells) to kill tumor cells, the bispecific antibody has good anti-cancer activity, and the bispecific antibody has the performance of reducing secretion of proinflammatory cytokines, is higher in safety, and can be applied to preparation of anti-tumor drugs. Good clinical application and drug development values are realized.

The invention discloses a compound microbial fermentation inoculant and application thereof in preparation of a metabiotic food taking multiple cereals as a matrix, and belongs to the technical field of microbial fermentation. According to the invention, a composite microbial fermentation inoculant is added into a multi-grain matrix containing a longan aril extract for fermentation, such that the post-generation food using multi-grain as the matrix is obtained. When the metabiotic food taking multiple cereals as the matrix is used for animal experiments, the blood pressure reduction rate of the compound group is higher, the fasting blood glucose value and the area under a curve are lower, the body weight and the TC value are smaller, the proinflammatory cytokines IL-1beta, IL-6 and TNF-alpha are smaller, and chao and ce indexes are larger. Compared with single use of the compound microbial fermentation inoculant, the longan aril extract or the multi-grain matrix, the metabiotic food which takes the multi-grain matrix and is obtained by the compound microbial fermentation inoculant has good effects of reducing blood pressure, reducing blood sugar and reducing blood fat, and can reduce inflammatory response, remove body toxins and regulate intestinal functions.

The invention provides application of injectable bioactive hydrogel in treatment of recurrent abortion, and relates to the technical field of biomedicine, and the technical key points are as follows: aldehydic hyaluronic acid and chitosan are connected in parallel, the injectable bioactive hydrogel is developed, and the hydrogel is loaded with LIF, VEGF, IL-11 and valproic acid to enhance regeneration activity. According to the application, the effect is evaluated in vitro through a specific verification experiment. Results show that the hydrogel prepared by the application shows rapid gelation, good biocompatibility and factor loading capacity, and enhances the proliferation of human endometrial stromal cells and the vascularization capacity of human umbilical vein endothelial cells. In macrophages, the expression of a proinflammatory cytokine is down-regulated, and the expression of an anti-inflammatory cytokine IL-10 is up-regulated. In conclusion, the HA-CHO / chitosan hydrogel in the application supports endometrial regeneration by synergistically promoting proliferation, angiogenesis, immune regulation and receptivity.

The invention provides a 3-hydroxypyrone derivative as well as a preparation method and application thereof, the compound can effectively inhibit release of proinflammatory cytokines in lipopolysaccharide-induced microglial cells, inhibit release of NO by the lipopolysaccharide-induced microglial cells, inhibit apoptosis of polysaccharide-induced microglial cells, and inhibit apoptosis of lipopolysaccharide-induced microglial cells. The compound has excellent anti-neuroinflammation activity and neuroprotective effect, the activity of the compound is superior to that of positive controls such as curcumin and hydrocortisone, and the compound can be used for preventing and / or treating neuroinflammation and neurodegenerative diseases.

Embodiments of the instant disclosure relate to intervention and / or treatment of autism spectrum disorder (ASD). Certain embodiments relate to treating a subject having ASD with one or more proinflammatory cytokines. In some embodiments, the one or more proinflammatory cytokines include, but are not limited to, granulocyte-macrophage colony-stimulating factor (GM-CSF) or derivative thereof, or fusion polypeptide thereof, or recombinant thereof. Other embodiments include a mouse model for assessing efficacy of treatment of ASD in humans and other mammals.

The invention relates to application of an organic compound in preparation of a medicine for preventing or treating neuroinflammation related diseases, and belongs to the technical field of medicinal chemistry. It is found that the organic compound with the chemical structural formula shown in the formula (I)-(IV) can remarkably inhibit the expression level of proinflammatory factors and chemotactic factors in a microglial cell inflammation model and has a broad-spectrum anti-inflammatory effect, and therefore the organic compound has the effect of preventing or treating neuroinflammation related diseases. The invention develops new application of the organic compounds as shown in the formulas (I)-(IV), and also provides a new therapeutic drug for preventing or treating neuroinflammation related diseases.

The invention belongs to the technical field of traditional Chinese medicine, and particularly relates to a traditional Chinese medicine composition for relieving depression and clearing collaterals and a preparation, a pharmaceutical composition and application thereof. The traditional Chinese medicine composition is prepared from the following raw material medicines in parts by weight: 6-12 parts of radix bupleuri, 9-15 parts of radix curcumae, 6-12 parts of rhizoma acori graminei, 3-9 parts of fructus gardeniae, 3-9 parts of polygala tenuifolia, 9-15 parts of radix paeoniae rubra and 9-20 parts of cortex albiziae. The traditional Chinese medicine composition provided by the invention can be used for remarkably improving depression-like behaviors of mice with depression, reversing synaptic injury and improving the expression of synaptic associated proteins SYP and PSD-95. The anti-depression mechanism of the traditional Chinese medicine composition is that the traditional Chinese medicine composition has the effects of synergistically inhibiting activation of microglial cells and reducing the level of proinflammatory cytokines such as Tnf alpha, Il1beta and Il6, so that neuroinflammation is remarkably inhibited, and the traditional Chinese medicine composition has the advantages of novel formula, definite mechanism and definite curative effect for treating depression, particularly patients with anxiety and dysphoria symptoms.

The present application relates to the technical field of biological medicine engineering, and provides application of RBFOX2 inhibitor in treatment of inflammatory bowel disease, and particularly relates to the role of interfering RNA or antisense oligonucleotide or recombinant expression vector targeting RBFOX2 coding sequence in preparation of products for treating colitis and its related symptoms and / or other complications, and also relates to corresponding recombinant vectors or pharmaceutical compositions. The RBFOX2 inhibitor can effectively reduce the level of proinflammatory cytokines, inhibit the activation of macrophages, has effective application value in relieving and treating colonic inflammation and other symptoms and / or other complications of inflammatory bowel disease, provides a new target for treatment of inflammatory bowel disease, and has wide clinical application prospect.

The present invention belongs to the field of biomedicine technology, and specifically discloses the application of Lactobacillus delbrueckii surface protein in the preparation of products that improve intestinal inflammation. The new use of Lactobacillus delbrueckii surface protein provided by the present invention, including the application in the preparation of a medicine for preventing and / or treating ulcerative colitis. Cell and animal experimental results show that Lactobacillus delbrueckii surface protein can alleviate DSS-induced ulcerative colitis in mice, improve weight loss, shortened colon length and colon mucosal damage, reduce proinflammatory cytokine (such as IL-1β, IL-6) content in the colon, increase anti-inflammatory cytokine (such as IL-10) content, reduce proinflammatory macrophage ratio in spleen and colon, inhibit macrophage proinflammatory phenotype, can be used for the preparation of products that improve intestinal inflammation, and has good application prospects and potential clinical treatment value.

The invention relates to pharmaceutics, and more particularly to gastroenterology, and can be used for the prophylaxis or treatment of inflammatory diseases of the gastrointestinal tract. What is described is the use of trimebutine maleate to achieve a maximum change in the level of the proinflammatory cytokines IL-1, IL-6, TNF-α, NF-κB and the anti-inflammatory cytokine IL-10 in the gastrointestinal tract for the prophylaxis or treatment of acute and chronic inflammatory diseases of the gastrointestinal tract.

This invention proposes an anti-CD3 antibody or its antigen-binding fragment and its applications. It comprises: heavy chain variable region CDRs and light chain variable region CDRs; wherein the heavy chain variable region CDRs have an amino acid sequence as shown in any one of SEQ ID NO: 1-3, 7-8, and 74-86 or a conserved modified form thereof; and / or the light chain variable region CDRs have an amino acid sequence as shown in any one of SEQ ID NO: 4-6, 9, and 87-92 or a conserved modified form thereof. The anti-CD3 antibody or its antigen-binding fragment of this invention can bind to human CD3 protein and can reduce the production of pro-inflammatory cytokines. Bispecific antibodies constructed using this antibody exhibit high PBMC-based tumor-killing activity and weak pro-inflammatory cytokine secretion-promoting properties. Therefore, pharmaceutical compositions prepared using this anti-CD3 antibody or its antigen-binding fragment or its multispecific antibody have better safety and high clinical application and drug development value.

The invention relates to application of rosa rugosa in preparation of a medicine for treating IBD (infectious bursal disease). According to the invention, firstly, it is found that the branchlet rose has a repairing effect on damage caused by IBD; researches find that the aqueous extract of rugosa branchlet can play a role by repairing intestinal barriers and inhibiting TLR4, TLR9 and proinflammatory cytokines, so that the aqueous extract of rugosa branchlet is beneficial to treatment of IBD. The invention provides an application prospect of the rosa rugosa in preparation of the medicine for treating IBD.

This invention discloses a novel use of carvedilol or its salts and compositions, as well as the composition and its preparation method. The β-blocker or pharmaceutical composition provided by this invention has good efficacy in preventing, treating, and / or alleviating drug-induced liver injury, effectively reducing mortality caused by this disease; simultaneously, it can significantly reduce serum transaminase levels, alleviate symptoms such as liver and spleen edema, and has a good inhibitory effect on pro-inflammatory cytokines. Furthermore, experimental results further indicate that the combination of the β-blocker and pharmaceutically acceptable excipients (steviosides and / or glycyrrhizate) has good safety and is easily dissolved, released, and / or absorbed, improving the bioavailability of carvedilol and exhibiting a synergistic effect, showing promising application prospects.

The invention discloses prevention and treatment of diseases by stimulating TRPV1 + sensory nerves. Specifically, the invention discloses application of a substance for stimulating TRPV1 + sensory nerves in preparation of products for prevention, treatment or adjuvant treatment of inflammatory diseases, autonomic nerve dysfunction diseases or adrenal insufficiency diseases, and application of the substance for stimulating TRPV1 + sensory nerves in preparation of products for inhibiting proinflammatory cytokines and products for promoting anti-inflammatory cytokines. The TRPV1 ion channel agonist disclosed by the invention can obviously and effectively inhibit the expression of numerous proinflammatory cytokines and obviously improve the expression of anti-inflammatory cytokines IL10, so that not only is the physiological status of an inflammatory mouse obviously improved, but also the survival rate of the inflammatory mouse is obviously improved; meanwhile, the spleen function can be adjusted, expression of spleen pro-inflammatory genes is remarkably inhibited, generation of catecholamine is increased, and secretion of cortisol hormones is promoted. The invention has wide clinical application value in prevention and treatment of related diseases.

The application discloses a kind of composite microbial fermentation inoculant and its application in metagenomic food preparation with multi-grain as substrate, belong to the field of microbial fermentation technology.The application adds composite microbial fermentation inoculant into multi-grain substrate containing longan meat extract to obtain metagenomic food with multi-grain as substrate.The metagenomic food with multi-grain as substrate is used for animal experiment, and the blood pressure reduction rate of complex group is higher, the fasting blood glucose value and the area under curve are lower, the body weight and TC value are smaller, the proinflammatory cytokines IL-1β, IL-6 and TNF-α are smaller, and the chao and ace index are larger.It is shown that compared with the use of composite microbial fermentation inoculant, longan meat extract or multi-grain substrate alone, the metagenomic food with multi-grain as substrate obtained by the application has good effects of reducing blood pressure, reducing blood sugar and reducing blood lipid, can reduce inflammatory response, remove body toxins and regulate intestinal function.

The invention relates to a skin injury organ model and a method for screening drugs by using the skin injury organ model, and the skin injury organ model is characterized in that skin cells, accessory structures, nerve cells, fat cells and the like form structures similar to actual skin by using an air-liquid interface skin organ preparation technology; and the damaged skin is prepared by irradiating the skin-like organ with ultraviolet rays which actually reach the ground surface. In the present invention, the skin barrier is damaged and the activity of a matrix proteolytic enzyme is improved to promote the decomposition of collagen while increasing the secretion of pro-inflammatory cytokines by irradiating with solar-simulated ultraviolet light comprising 94.5% ultraviolet light (UV-A) and 5.5% ultraviolet light (UV-B), thereby well simulating the characteristics of skin injury caused by ultraviolet light. Therefore, the invention can be used as a model of skin injury and photoaging caused by ultraviolet rays, and can be useful in potential therapeutic drug screening.

The invention relates to a protein for treating new coronavirus and application thereof. The protein is LSR and CRD1 oligopeptide protein derived from the LSR. The protein disclosed by the invention has a relatively strong inhibition effect on original strains and various variant strains of the new coronavirus, and can be used as a medicine for treating diseases caused by the new coronavirus. Through verification, the protein drug provided by the invention can have a strong and broad-spectrum antiviral effect on new crown original strains and mutant strains thereof (Omicro B521 and XBB) from the cellular level, the organoid level and the tissue level, the pathological injury of intestinal tracts and lungs is improved, and the level of proinflammatory cytokines is reduced. In addition, the LSR and the oligopeptide medicine CRD1 derived from the LSR can effectively inhibit the combination of Spike and ACE2, so that the infection rate of SARS-CoV-2 is reduced. The PEG-LSR protein and the CRD1 oligopeptide derived from the LSR are expected to have the potential of preventing and / or treating new variant strains appearing in the future and other various coronaviruses taking ACE2 as receptors.

The application discloses a blood purification membrane for removing proinflammatory cytokines and a preparation method thereof. The method comprises the following steps: dissolving a film-forming material and an additive in a solvent to obtain a homogeneous casting solution; preparing a hollow fiber plasma separation membrane by using a non-solvent phase inversion method; and constructing a proinflammatory cytokine adsorption functional layer on the outer surface of the hollow fiber plasma separation membrane to obtain a homogeneous blood purification membrane. The blood purification membrane prepared by the method has the plasma separation function, can separate inflammatory cytokines from the inner side of the membrane to the outer side of the membrane, and has excellent blood compatibility on the inner surface of the membrane and the adsorption and removal function of pathogenic toxins and proinflammatory cytokines on the outer surface of the membrane. In the construction process, the two functions do not interfere with each other, the blood compatibility of the material is improved, the removal rate of the pathogenic toxins is not affected, and the problem of the reduction of the toxin adsorption and removal effect caused by the existing technology for improving the blood compatibility of the plasma perfusion adsorption resin is solved.

The invention discloses application of ethyl sulfate in preparation of a medicine for preventing and / or treating inflammatory bowel diseases, and belongs to the technical field of medicines. The invention finds that ethyl sulfate has the effect of preventing and / or treating inflammatory bowel disease for the first time: the ethyl sulfate can obviously improve the survival index of an inflammatory bowel disease model mouse and reduce the disease activity index; the symptoms of weight loss, stool character, inflammation-related diarrhea and bloody stool are relieved; the length of colon tissue is improved, and the size and number of tumors in colorectum are reduced; the pharmaceutical composition has the effects of inhibiting the level of proinflammatory cytokines (TNF-alpha, IL-8, IL-1beta and IL-6), recovering the level of anti-inflammatory cytokines (IL-10 and INF-gamma), inhibiting the enzymatic activity of MPO and MDA and improving the enzymatic activity of SOD and GSH-Px, so that the inflammatory reaction and oxidative stress reaction in the inflammatory bowel disease microenvironment are improved, and the pharmaceutical composition has the pharmacological action of preventing and / or treating the inflammatory bowel disease.

The invention relates to an application of bacillus subtilis ST-1086. After the bacillus subtilis ST-1086, the postbiotics or the composition containing the bacillus subtilis ST-1086 and the postbiotics are co-cultured with macrophage RAW264.7 cells, the secretion amount of proinflammatory cytokines TNF-alpha, IL-6 and IL-1beta of the RAW264.7 cells and the secretion amount of anti-inflammatory cytokines IL-10 of the RAW264.7 cells can be increased, the immune enhancement effect is achieved by regulating and controlling the network balance of the cytokines, and then the effect of improving the immunity is achieved. The bacillus subtilis ST-1086 is classified and named as bacillus subtilis, and the preservation number of the bacillus subtilis ST-1086 is CGMCC (China General Microbiological Culture Collection Center) No. 17895.

The invention discloses application of a waxberry seed alcohol extract in preparation of a medicine for treating colitis. The waxberry seed alcohol extract inhibits the generation of LPS-induced proinflammatory mediators (NO) and proinflammatory cytokines (TNF-alpha, IL-6 and IL-1beta) under the condition of no cytotoxicity; the waxberry seed alcohol extract inhibits the expression of the protein of LPS-induced pro-inflammatory mediator enzymes (iNOS and COX-2); the waxberry seed alcohol extract not only inhibits nuclear transfer of NF-kappa B by reducing phosphorylation and degradation of I kappa B alpha, but also inhibits phosphorylation of MPAKs (ERK, p38 and JNK); animal experiments prove that the waxberry seed alcohol extract shortens mouse colon, reduces mouse DAI score, alleviates mouse colon tissue damage, reduces the content of IL-6, IL-1beta, TNF-alpha and MDA in mouse colon tissue and serum, and enhances the activity of CAT and SOD in mouse colon tissue and serum. Therefore, the waxberry seed alcohol extract has a remarkable anti-inflammatory effect in vivo and in vitro, and can be used for treating colitis.

The invention discloses lactobacillus helveticus capable of relieving rheumatoid arthritis and application of the lactobacillus helveticus, and belongs to the technical field of microorganisms. A strain of lactobacillus helveticus CCFM1501 is screened out, the lactobacillus helveticus CCFM1501 can produce cell wall protease, amino-peptidase and aromatic transaminase at high yield, and has the effect of relieving rheumatoid arthritis, and the specific effects are that the thickness of a posterior claw of a rat with rheumatoid arthritis is reduced, and knee joint injury is improved; the content of proinflammatory cytokines in the serum of rheumatoid arthritis rats is reduced, the content of anti-inflammatory cytokines IL-10 in the serum of the rheumatoid arthritis rats is increased, the content of arthritis specific antibodies in the serum of the rheumatoid arthritis rats is reduced, the mRNA relative expression quantity of colonic tight junction proteins ZO-1 and Occludin in the rheumatoid arthritis rats is increased, and the anti-inflammatory activity of the rheumatoid arthritis rats is improved. The content of acetic acid and butyric acid in excrement of rats with rheumatoid arthritis is increased.

The invention discloses an application of umbilical cord mesenchymal stem cells in treatment of immune-associated pneumonia, and relates to the technical field of biological medicines, and the technical key points are as follows: the umbilical cord mesenchymal stem cells (ucMSCs) are pre-stimulated by IFN-gamma, and a large amount of chemotactic factors can be secreted after the mesenchymal stem cells are activated, so that the immune-associated pneumonia can be effectively treated; further, T cells are attracted, and proliferation of the T cells and generation of proinflammatory cytokines are effectively inhibited; the IFN-gamma pre-stimulated hucMSCs are beneficial for improving the survival rate of CIP patients, and a new treatment thought is provided for the field.

The invention discloses a green extraction method of quercetin from kitchen waste pericarp and application thereof, and relates to the technical field of green extraction of natural products, the green extraction method comprises the following steps: S1, a pericarp pretreatment step; s2, preparing an extracting solution; s3, an extraction step; s4, a solid-liquid separation step; s5, an enrichment and purification step; according to the method disclosed by the invention, the dissolution efficiency and selectivity of the quercetin from the pericarp matrix are remarkably improved through the synergistic effect of enzymatic degradation and the deep eutectic solvent (DES) and assisted by physical energy, so that the recovery rate and the enrichment purity of the target component are improved, the subsequent purification burden is relieved, and the practical value of the extract is enhanced. The quercetin enrichment preparation can obviously inhibit the activation of an NF-kappa B signal channel and reduce the expression of downstream proinflammatory cytokines under a non-lethal administration concentration, so that the quercetin enrichment preparation shows the effects of reducing the activation of microglial cells and inhibiting neuroinflammatory response in an in-vitro cell model and an animal neuroinflammatory model; the pathological process related to neuroinflammation can be relieved or prevented.

The invention provides a ganoderma lucidum molecular ecological liquid extract obtained through specific fermentation and a preparation method and application thereof, and belongs to the technical field of microbial fermentation. According to the method, an improved fermentation culture medium is adopted, 5-8% of CO2 is introduced, fermentation is performed for 90-180 days at the temperature of 30-32 DEG C under the condition that the concentration of dissolved oxygen in the environment is kept to be 20-30%, and after purification, the extract of the ganoderma lucidum molecular ecological liquid is obtained. According to the myxomycete molecular ecological liquid prepared by the preparation method provided by the invention, the content of active ingredients for relieving the symptoms of the chronic obstructive pulmonary disease can be remarkably increased; moreover, an in-vitro cell experiment verifies that the extract of the ganoderma lucidum molecular ecological liquid has an inhibition effect on an A549 cell line, and an animal experiment further proves that the extract of the ecological liquid can regulate and control the expression level of proinflammatory cytokines, so that lung inflammation is inhibited, pathological injury of lung tissues is relieved, and local abnormal conditions of the lung are improved.